Bristol Myers Squibb ’s Investigational LPA1 Antagonist BMS-986278 Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis

PRINCETON, N.J.--(BUSINESS WIRE) May 22, 2023 -- Bristol Myers Squibb (NYSE: BMY) today announced results from a Phase 2 study evaluating BMS-986278, a potential first-in-class, oral, lysophosphatidic acid receptor 1 (LPA1) antagonist, in patients...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials